The 5 most recent market catalysts affecting $ZLAB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 14, 2026
Corporate Catalyst
Neutral
Impact 75
Zai Lab Announces Inclusion of Five Medicines in China's 2026 National Reimbursement Drug List
Zai Lab announced that five of its commercial products, including two new listings for generalized myasthenia gravis and schizophrenia treatments, have been included in China's 202…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 75
Zai Lab Announces $250 Million Private Placement
Zai Lab Limited announced a private placement of 11,340,000 ADSs at $22.04 per ADS, raising approximately $250 million. This PIPE financing, led by TCGX with participation from oth…
Oct 14, 2026
Corporate Catalyst
Neutral
Impact 65
Zai Lab To Present First Phase 1/1b Data On Atopic Dermatitis Candidate ZL-1503 In Healthy Volunteers On November 13
This headline represents a corporate catalyst for Zai Lab. The presentation of Phase 1/1b data, even in healthy volunteers, is a crucial early step in drug development. Positive sa…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Zai Lab shares are trading higher after the company reported better-than-expected Q2 sales results.
This headline represents a significant corporate catalyst for Zai Lab. Better-than-expected sales results directly impact a company's revenue and profitability outlook, often leadi…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Zai Lab Q2 EPS $(0.46) Misses $(0.06) Estimate, Sales $105.751M Beat $105.323M Estimate
Zai Lab's Q2 earnings report presents a mixed bag for investors. The substantial miss on EPS, falling short by over 600%, is a major negative catalyst and will likely lead to downw…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.